Role of Cytokines in Tumor Immunity and Immune Tolerance to Cancer

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Cancer Immunology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-3-662-44006-3_7
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• TAMeless traitors: macrophages in cancer progression and metastasis

  2017cited by this paper
• Targeting latency-associated peptide promotes antitumor immunity

  2017cited by this paper
• Dual Roles of IL-27 in Cancer Biology and Immunotherapy

  2017cited by this paper
• γδ T Cells: Unexpected Regulators of Cancer Development and Progression.

  2017cited by this paper
• Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody

  2017cited by this paper
• Suppression Colitis and Colitis-Associated Colon Cancer by Anti-S100a9 Antibody in Mice

  2017cited by this paper
• Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

  2017cited by this paper
• Interleukin-35 Limits Anti-Tumor Immunity.

  2016cited by this paper
• Interleukin 4 inhibits TGF-β-induced-Foxp 3 + T cells and generates , in combination with TGF-β , Foxp 3 − effector T cells that produce interleukins 9 and 10

  2016cited by this paper
• Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

  2015cited by this paper
• Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway

  2015cited by this paper
• Role of osteopontin in the pathophysiology of cancer.

  2014cited by this paper
• Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

  2014cited by this paper
• IL-17 producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity

  2014cited by this paper
• Interleukin 12: still a promising candidate for tumor immunotherapy?

  2014cited by this paper
• Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis.

  2014cited by this paper
• Th9 cells: differentiation and disease

  2013cited by this paper
• Cytokine patterns in patients with cancer: a systematic review.

  2013cited by this paper
• Tumor-Derived IL-35 Promotes Tumor Growth by Enhancing Myeloid Cell Accumulation and Angiogenesis

  2013cited by this paper
• PGE2 differentially regulates monocyte-derived dendritic cell cytokine responses depending on receptor usage (EP2/EP4).

  2013cited by this paper
• At the Bedside: CTLA‐4‐ and PD‐1‐blocking antibodies in cancer immunotherapy

  2013cited by this paper
• IL-27 in tumor immunity and immunotherapy.

  2013cited by this paper
• Increased Th17 Cells in the Tumor Microenvironment Is Mediated by IL-23 via Tumor-Secreted Prostaglandin E2

  2013cited by this paper
• Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients

  2013cited by this paper
• Macrophage regulation of tumor responses to anticancer therapies.

  2013cited by this paper
• Critical Role of Dendritic Cell–Derived IL-27 in Antitumor Immunity through Regulating the Recruitment and Activation of NK and NKT Cells

  2013cited by this paper
• Targeting tumor-infiltrating macrophages to combat cancer.

  2013cited by this paper
• Human Prostate Tumor Antigen–Specific CD8+ Regulatory T Cells Are Inhibited by CTLA-4 or IL-35 Blockade

  2012cited by this paper
• Coordinated regulation of myeloid cells by tumours

  2012cited by this paper
• T-regulatory cells: key players in tumor immune escape and angiogenesis.

  2012cited by this paper
• Macrophages in Tumor Microenvironments and the Progression of Tumors

  2012cited by this paper
• Prostaglandin E2-induced IL-23p19 Subunit Is Regulated by cAMP-responsive Element-binding Protein and C/AATT Enhancer-binding Protein β in Bone Marrow-derived Dendritic Cells*

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Apoptotic tumor cells induce IL‐27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity

  2012cited by this paper
• IL-12 family cytokines: immunological playmakers

  2012cited by this paper
• Complexities of TGF-β Targeted Cancer Therapy

  2012cited by this paper
• The dynamic roles of TGF‐β in cancer

  2011cited by this paper
• Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis.

  2011cited by this paper
• Dual biological effects of the cytokines interleukin-10 and interferon-γ

  2011cited by this paper
• Identification of Epstein-Barr Virus–Induced Gene 3 as a Novel Serum and Tissue Biomarker and a Therapeutic Target for Lung Cancer

  2011cited by this paper
• In Vivo Expression of Interleukin-37 Reduces Local and Systemic Inflammation in Concanavalin A-Induced Hepatitis

  2011cited by this paper
• Interleukin 37 expression protects mice from colitis

  2011cited by this paper
• The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis

  2011cited by this paper
• Natural innate and adaptive immunity to cancer.

  2011cited by this paper
• Cutting Edge: Human Regulatory T Cells Require IL-35 To Mediate Suppression and Infectious Tolerance

  2011cited by this paper
• IRF4 Is a Suppressor of c-Myc Induced B Cell Leukemia

  2011cited by this paper
• Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Stable IL-10: a new therapeutic that promotes tumor immunity.

  2011cited by this paper
• The parallel lives of angiogenesis and immunosuppression: cancer and other tales

  2011cited by this paper
• Antibody targeting of TGF-β in cancer patients.

  2011cited by this paper
• A Role for IL-27 in Limiting T Regulatory Cell Populations

  2011cited by this paper
• Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy

  2011cited by this paper
• IL‐27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells

  2011cited by this paper
• TGFβ signalling: a complex web in cancer progression

  2010cited by this paper
• TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

  2010cited by this paper
• Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

  2010cited by this paper
• Differentiation of effector CD4 T cell populations (*).

  2010cited by this paper
• IL-35-mediated induction of a potent regulatory T cell population

  2010cited by this paper
• Identification of an IL-27/osteopontin axis in dendritic cells and its modulation by IFN-γ limits IL-17–mediated autoimmune inflammation

  2010cited by this paper
• The polarization of immune cells in the tumour environment by TGFβ

  2010influential reference
• Immune infiltration in human tumors: a prognostic factor that should not be ignored

  2010cited by this paper
• The regulation of IL-10 production by immune cells

  2010cited by this paper
• IL-35 Stimulation of CD39+ Regulatory T Cells Confers Protection against Collagen II-Induced Arthritis via the Production of IL-10

  2010cited by this paper
• Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis

  2010cited by this paper
• A novel axis of innate immunity in cancer

  2010cited by this paper
• TGF-beta and 'adaptive' Foxp3(+) regulatory T cells.

  2010cited by this paper
• Interleukin-27 Acts as Multifunctional Antitumor Agent in Multiple Myeloma

  2010cited by this paper
• Immunologic and Therapeutic Synergy of IL-27 and IL-2: Enhancement of T Cell Sensitization, Tumor-Specific CTL Reactivity and Complete Regression of Disseminated Neuroblastoma Metastases in the Liver and Bone Marrow1

  2009cited by this paper
• IL‐17‐producing γδ T cells

  2009cited by this paper
• Protumor vs Antitumor Functions of IL-171

  2009cited by this paper
• Interleukin-10 Production by Th1 Cells Requires Interleukin-12-Induced STAT4 Transcription Factor and ERK MAP Kinase Activation by High Antigen Dose

  2009cited by this paper
• IL-27 Blocks RORc Expression to Inhibit Lineage Commitment of Th17 Cells

  2009cited by this paper
• Programming for CD8 T Cell Memory Development Requires IL-12 or Type I IFN1

  2009cited by this paper
• Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

  2009cited by this paper
• IL-27 Is a Key Regulator of IL-10 and IL-17 Production by Human CD4+ T Cells1

  2009cited by this paper
• Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.

  2009cited by this paper
• Cancer Associated Fibroblasts Promote Tumor Growth and Metastasis by Modulating the Tumor Immune Microenvironment in a 4T1 Murine Breast Cancer Model

  2009cited by this paper
• IL-17 and Th17 Cells.

  2009cited by this paper
• Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments.

  2009cited by this paper
• Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity.

  2009cited by this paper
• Tumor‐specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti‐tumor immunity

  2009cited by this paper
• IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway

  2009cited by this paper
• Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells

  2009cited by this paper
• Unravelling the mechanisms of help for CD8+ T cell responses

  2009cited by this paper
• Endogenous IL-17 contributes to reduced tumor growth and metastasis.

  2009cited by this paper
• Non-Redundant Role for IL-12 and IL-27 in Modulating Th2 Polarization of Carcinoembryonic Antigen Specific CD4 T Cells from Pancreatic Cancer Patients

  2009cited by this paper
• IL-23 Drives Pathogenic IL-17-Producing CD8+ T Cells1

  2009cited by this paper
• Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10

  2009cited by this paper
• Type 17 CD8+ T cells display enhanced antitumor immunity.

  2009cited by this paper
• Tumor Microenvironments Direct the Recruitment and Expansion of Human Th17 Cells

  2009cited by this paper
• The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.

  2008cited by this paper
• Tumor-specific Th17-polarized cells eradicate large established melanoma.

  2008cited by this paper
• Increased Osteopontin Expression in Dendritic Cells Amplifies IL-17 Production by CD4+ T Cells in Experimental Autoimmune Encephalomyelitis and in Multiple Sclerosis1

  2008cited by this paper
• Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17.

  2008cited by this paper
• IL-6, in Synergy with IL-7 or IL-15, Stimulates TCR-Independent Proliferation and Functional Differentiation of CD8+ T Lymphocytes1

  2008cited by this paper
• TGF-beta: a master of all T cell trades.

  2008cited by this paper
• IL-27 inhibits the development of regulatory T cells via STAT3.

  2008cited by this paper
• TGFbeta in Cancer.

  2008cited by this paper
• IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: a model for early basal-type mammary carcinogenesis.

  2008cited by this paper

• Modulating tumor mechanics and vascular barriers to enhance chemotherapy efficacy in pancreatic tumors and melanoma

  2025cites this paper
• Cyclooxygenase-2 as a potential therapeutic target in the treatment of chemoresistant glioblastomas

  2025cites this paper
• High Copy Number Variations Correlate with a Pro-Tumoral Microenvironment and Worse Prognosis in Acral Lentiginous Melanoma

  2025cites this paper
• The functional TNF-α−308G > a single-nucleotide polymorphism (rs1800629): association with the predictive indices of breast cancer carcinogenesis

  2024cites this paper
• Emerging Immunotherapy Approaches for Treating Prostate Cancer

  2023cites this paper
• Impact of IL-10 Promoter Polymorphisms and IL-10 Serum Levels on Advanced Laryngeal Squamous Cell Carcinoma and Survival Rate

  2021cites this paper
• Combination of Gas Plasma and Radiotherapy Has Immunostimulatory Potential and Additive Toxicity in Murine Melanoma Cells In Vitro

  2020cites this paper
• IL‐35, a hallmark of immune‐regulation in cancer progression, chronic infections and inflammatory diseases

  2018influential citation
• Novel adenoviral vaccine encoding multiple tumor neo-antigens in combination with checkpoint blockade as a strategy for more effective cancer treatment

  2018cites this paper
• Positive correlation between interleukin-1 receptor antagonist gene 86bp VNTR polymorphism and colorectal cancer susceptibility: a case-control study

  2018cites this paper